Nanobiotix (NBTX) Competitors

Pharvaris (NASDAQ:PHVS) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.

Does the MarketBeat Community prefer PHVS or NBTX?

Pharvaris received 24 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 66.04% of users gave Pharvaris an outperform vote while only 64.71% of users gave Nanobiotix an outperform vote.

Company	Underperform	Outperform
Pharvaris	Outperform Votes 35 66.04%	Underperform Votes 18 33.96%
Nanobiotix	Outperform Votes 11 64.71%	Underperform Votes 6 35.29%

Do institutionals & insiders hold more shares of PHVS or NBTX?

38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Is PHVS or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-38.52%	-36.69%
Nanobiotix	N/A	N/A	N/A

Do analysts recommend PHVS or NBTX?

Pharvaris currently has a consensus target price of $39.25, suggesting a potential upside of 104.96%. Nanobiotix has a consensus target price of $12.00, suggesting a potential upside of 273.25%. Given Nanobiotix's higher probable upside, analysts clearly believe Nanobiotix is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nanobiotix	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, PHVS or NBTX?

Nanobiotix has higher revenue and earnings than Pharvaris.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$109.18M	-$2.80	-6.84
Nanobiotix	$39.18M	3.87	-$42.97M	N/A	N/A

Which has more volatility and risk, PHVS or NBTX?

Pharvaris has a beta of -3.06, suggesting that its stock price is 406% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.

Does the media refer more to PHVS or NBTX?

In the previous week, Pharvaris and Pharvaris both had 2 articles in the media. Nanobiotix's average media sentiment score of 1.00 beat Pharvaris' score of 0.64 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nanobiotix beats Pharvaris on 9 of the 12 factors compared between the two stocks.